Title:
単離抗体、医薬組成物、単離抗体結合体、ダイマー化阻害方法、シグナル伝達阻害方法、管新生阻害方法、治療方法、および断片検出方法
Document Type and Number:
Japanese Patent JP7339325
Kind Code:
B2
Abstract:
An isolated antibody, comprising heavy chain complementary determining regions CDR1, CDR2, and CDR3 from a heavy chain variable region sequence having SEQ ID NO: 1 or 3; light chain complementary determining regions CDR1, CDR2, and CDR3 from a light chain variable region sequence having SEQ ID NO: 2 or 4; wherein the antibody binds specifically to both vascular endothelial growth factor receptor-2 (VEGFR2) and vascular endothelial growth factor receptor-3 (VEGFR3).
Inventors:
Shi, Nen-Yao
Ryu, Ko Ji-eun
Chen, Li-Tsung
Hung, Wen-Chun
Chen, Yun-chan
Xiao, Quan-Chun
Shen, Satai
Ryu, Ko Ji-eun
Chen, Li-Tsung
Hung, Wen-Chun
Chen, Yun-chan
Xiao, Quan-Chun
Shen, Satai
Application Number:
JP2021500784A
Publication Date:
September 05, 2023
Filing Date:
March 20, 2019
Export Citation:
Assignee:
National Health Research Institutes
International Classes:
C07K16/28; A61K39/395; A61P1/02; A61P1/04; A61P1/16; A61P1/18; A61P5/14; A61P11/00; A61P13/08; A61P13/10; A61P13/12; A61P15/00; A61P17/00; A61P21/00; A61P35/00; A61P43/00; C07K16/46; C12N15/13; G01N33/53
Foreign References:
| WO2017004254A1 |
Other References:
Int J Mol Sci, 2012 Dec 20, vol. 14, no. 1, pp. 88-107
Mol Cancer Ther, 2005 Mar, vol. 4, no. 3, pp. 427-434
Mol Cancer Ther, 2005 Mar, vol. 4, no. 3, pp. 427-434
Attorney, Agent or Firm:
Patent Attorney Corporation Hattori International Patent Office
Masaki Hattori
Masaki Hattori